Imugene & Arovella collaborate for a preclinical trial to explore treatment options for solid cancers

Image Source: Company Announcement


  • Imugene Limited and Arovella Therapeutics have inked a research agreement for a strategic collaboration.
  • The two biotech firms will conduct a preclinical trial of ALA’s iNKT cell therapy (CAR19-iNKT) and IMU’s onCARlytics (CF33-CD19) platform to target solid tumours.
  • The study will be exploring the potential of using the iNKT cell therapy in cancers, addressing a major unmet need.

Even as the world is witnessing a revolution in medical technology, cancer continues to be a major health issue. Around 19.3 million new cancer cases (18.1 million excluding non-melanoma skin cancer) occurred in the year 2020 across the world. Also, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, as per WHO.

Two biotech companies, Imugene Limited (ASX:IMU) and Arovella Therapeutics (ASX:ALA), have joined hands to contribute to the ongoing cell therapy revolution in cancer treatment. The two firms have entered a strategic collaboration to work on a combination of an off-the-shelf cell therapy and oncolytic virus to detect and eliminate solid tumours.

©2022 Kalkine Media®

As per the company announcement, the collaboration holds the potential to bring in long- and short-term business benefits to both firms as it will strengthen their foothold in the global cancer therapeutics market, which, according to Precedence Research, is likely to touch AU$366 billion by 2030. The market is growing at a compound annual growth rate of 9.1%.



The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and